Evolution Wealth Advisors’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Evolution Wealth Advisors’s Portfolio GBT Stock Details GBT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-145	Closed	-$4K	–	666
2021 Q3	$4K	Sell	145 -221	-60%	-$6.5K	﹤0.01%	585
2021 Q2	$13K	Hold	366	–	–	﹤0.01%	371
2021 Q1	$15K	Sell	366 -54	-13%	-$2.48K	﹤0.01%	349
2020 Q4	$18K	Hold	420	–	–	﹤0.01%	279
2020 Q3	$23K	Buy	420 +51	+14%	+$3.24K	0.01%	259
2020 Q2	$23K	Sell	369 -68	-16%	-$4.66K	0.01%	197
2020 Q1	$22K	Buy	437 +81	+23%	+$5.43K	0.01%	149
2019 Q4	$28K	Buy	356 +332	+1,383%	+$19.7K	0.01%	195
2019 Q3	$1K	Sell	24 -255	-91%	-$13.3K	﹤0.01%	473
2019 Q2	$15K	Buy	+279	New	+$16K	0.01%	150

Other funds holding GBT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Evolution Wealth Advisors's GBT Position: Q4 2021 in Review

Evolution Wealth Advisors sold out of Global Blood Therapeutics, Inc. (GBT) in Q4 2021, closing a stake of 145 shares — an estimated $4K sold.

Evolution Wealth Advisors first reported a position in GBT in Q2 2019 and held it in 10 quarters. The position peaked at $28K in Q4 2019. 206 funds tracked by Wall St. Rank hold GBT as of Q4 2021.

Evolution Wealth Advisors reported no remaining Global Blood Therapeutics, Inc. position as of Q4 2021 after selling out during the quarter.
Evolution Wealth Advisors sold 145 Global Blood Therapeutics, Inc. shares in Q4 2021, an estimated $4K.
Evolution Wealth Advisors first reported a position in Global Blood Therapeutics, Inc. in Q2 2019 and held it in 10 quarters.
Evolution Wealth Advisors's Global Blood Therapeutics, Inc. position peaked at $28K in Q4 2019.
206 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q4 2021.

Based on Evolution Wealth Advisors's 13F filing for Q4 2021, filed 28 Jan 2022.